Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001193125-23-069081
Filing Date
2023-03-13
Accepted
2023-03-13 16:18:56
Documents
1
Group Members
ATHYRIUM FUNDS GP HOLDINGS LLCATHYRIUM OPPORTUNITIES ASSOCIATES CO-INVEST LLCATHYRIUM OPPORTUNITIES ASSOCIATES III GP LLCATHYRIUM OPPORTUNITIES ASSOCIATES III LPATHYRIUM OPPORTUNITIES III ACQUISITION 2 LPATHYRIUM OPPORTUNITIES III ACQUISITION LPATHYRIUM O

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d473842dsc13da.htm SC 13D/A 196571
  Complete submission text file 0001193125-23-069081.txt   198711
Mailing Address 4330 LA JOLLA VILLAGE DRIVE SUITE 200 SAN DIEGO CA 92122
Business Address 4330 LA JOLLA VILLAGE DRIVE SUITE 200 SAN DIEGO CA 92122 855-293-2639
BIORA THERAPEUTICS, INC. (Subject) CIK: 0001580063 (see all company filings)

EIN.: 273950390 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-91551 | Film No.: 23727559
SIC: 2834 Pharmaceutical Preparations

Mailing Address 505 FIFTH AVENUE, FLOOR 18 NEW YORK NY 10017
Business Address 505 FIFTH AVENUE, FLOOR 18 NEW YORK NY 10017 646-434-1636
Athyrium Opportunities 2020 LP (Filed by) CIK: 0001815261 (see all company filings)

EIN.: 850719033 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A